Search

Your search keyword '"Vena, Gino Antonio"' showing total 247 results
Start Over Author "Vena, Gino Antonio"
247 results on '"Vena, Gino Antonio"'

3. Keratosis Pilaris-like Eruption during Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors: Literature Review and Report of a Case Related to Imatinib

Author

Ambrogio, Francesca, primary, Poli, Melita Anna, additional, Lospalluti, Lucia, additional, Lettini, Teresa, additional, Cassano, Nicoletta, additional, Vena, Gino Antonio, additional, Ingravallo, Giuseppe, additional, Cazzato, Gerardo, additional, and Foti, Caterina, additional

Published
2023
Full Text
View/download PDF

4. Granulomatous Secondary Syphilis: A Case Report with a Brief Overview of the Diagnostic Role of Immunohistochemistry

Author

Ambrogio, Francesca, primary, Cazzato, Gerardo, additional, Foti, Caterina, additional, Grandolfo, Mauro, additional, Mennuni, Gisella Biagina, additional, Vena, Gino Antonio, additional, Cassano, Nicoletta, additional, Lettini, Teresa, additional, Castronovi, Cosimo, additional, Ingordo, Vito, additional, Romita, Paolo, additional, and Filotico, Raffaele, additional

Published
2023
Full Text
View/download PDF

6. Keratosis Pilaris-like Eruption during Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors: Literature Review and Report of a Case Related to Imatinib.

Author

Ambrogio, Francesca, Poli, Melita Anna, Lospalluti, Lucia, Lettini, Teresa, Cassano, Nicoletta, Vena, Gino Antonio, Ingravallo, Giuseppe, Cazzato, Gerardo, and Foti, Caterina

Subjects
PROTEIN-tyrosine kinase inhibitors, CHRONIC myeloid leukemia, IMATINIB, CHRONIC leukemia, ACNEIFORM eruptions, KERATOSIS
Abstract

The advent of tyrosine kinase inhibitors (TKIs) blocking BCR-ABL activity has revolutionized the therapeutic management of patients with chronic myeloid leukemia (CML). Adverse cutaneous reactions (ACRs) are common nonhematologic adverse events associated with the use of BCR-ABL TKIs. A characteristic pattern of eruption resembling keratosis pilaris (KP) has been described in patients treated with these drugs, especially nilotinib and dasatinib. The pathogenesis of this ACR is still unknown. This type of reaction appears to be uncommon with imatinib. Here, we report the case of an elderly patient with an asymptomatic KP-like eruption, which appeared one month after starting treatment with imatinib for CML. The case presentation is accompanied by a review of similar reactions in patients with CML treated with BCR-ABL inhibitors, attempting to make an excursus on the molecular targets of such drugs and possible mechanisms underlying this ACR. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. The GENDER ATTENTION Observational Study: Gender and Hormonal Status Differences in the Incidence of Adverse Events During Cyclosporine Treatment in Psoriatic Patients

Author

Colombo, Delia, Banfi, Giuseppe, Cassano, Nicoletta, Graziottin, Alessandra, Vena, Gino Antonio, Fiori, Giovanni Gualberto, Zagni, Emanuela, Stingeni, Luca, Chimenti, Sergio, Berardesca, Enzo, Micali, Giuseppe, Albertini, Giuseppe, De Simone, Clara, Bellia, Gilberto, Amato, Salvatore, Ayala, Fabio, Bardazzi, Ferderico, Bernengo, Maria Grazia, Bongiorno, Maria Rita, Borroni, Giovanni, Calvieri, Stefano, Pinton, Piergiacomo Calzavara, Cannarozzo, Calcedonio, Cannavò, Serafinella Patrizia, Cattaneo, Angelo, Ceschini, Rossella, Colombo, Enrico, Congedo, Maurizio, Cusano, Francesco, De Pità, Ornella, Di Nuzzo, Sergio, Donadio, Dario, Donelli, Stefano, Filotico, Raffaele, Flori, Maria Laura, Germino, Maurizio, Girolomoni, Giampiero, Kokelj, Franco, Lanzoni, Anna, Lembo, Giuseppe, Locatelli, Andrea, Magnoni, Cristina, Marconi, Marco, Motolese, Alberico, Papini, Manuela, Parodi, Aurora, Pau, Monica, Peris, Ketty, Piaserico, Stefano, Piccirillo, Angelo, Potenza, Concetta, Ricotti, Giuseppe, Sedona, Patrizio, Stinco, Giuseppe, Valenti, Giancarlo, Fornasa, Cleto Veller, Zichichi, Leonardo, Ori, Alessandra, Amici, Christian, Zullo, Alessandro, Simoni, Lucia, Lanci, Nicole, Longagnani, Chiara, Sala, Saide, Trevisan, Francesca, Magri, Giovanna, and On behalf of the GENDER ATTENTION study group

Published
2017
Full Text
View/download PDF

12. A 39-year-old woman with non-follicular pustules on targetoid plaques during treatment for in vitro fertilization and embryo transfer

Author

Poli, Melita Anna, primary, Ambrogio, Francesca, additional, De Marco, Aurora, additional, Messina, Raffaella, additional, Vena, Gino Antonio, additional, Cassano, Nicoletta, additional, Cazzato, Gerardo, additional, Filotico, Raffaele, additional, Bonamonte, Domenico, additional, Romita, Paolo, additional, and Foti, Caterina, additional

Published
2022
Full Text
View/download PDF

16. Circulating Irisin Levels in Patients with Chronic Plaque Psoriasis

Author

Ambrogio, Francesca, primary, Sanesi, Lorenzo, additional, Oranger, Angela, additional, Barlusconi, Chiara, additional, Dicarlo, Manuela, additional, Pignataro, Patrizia, additional, Zerlotin, Roberta, additional, Romita, Paolo, additional, Favoino, Elvira, additional, Cazzato, Gerardo, additional, Cassano, Nicoletta, additional, Vena, Gino Antonio, additional, Foti, Caterina, additional, and Grano, Maria, additional

Published
2022
Full Text
View/download PDF

19. Analysis of clinical factors as possible predictors of response to omalizumab and relapse after treatment discontinuation in chronic spontaneous urticaria

Author

Foti, Caterina, primary, Romita, Paolo, additional, Ambrogio, Francesca, additional, Fanelli, Margherita, additional, Panebianco, Rosanna, additional, Vena, Gino Antonio, additional, Cassano, Nicoletta, additional, Ragusa, Mariagrazia, additional, Giuffrida, Roberta, additional, Papaianni, Valeria, additional, Borgia, Francesco, additional, Cannavò, Serafinella Patrizia, additional, and Guarneri, Fabrizio, additional

Published
2021
Full Text
View/download PDF

22. The Intriguing Links between Psoriasis and Bullous Pemphigoid.

Author

Maronese, Carlo Alberto, Cassano, Nicoletta, Genovese, Giovanni, Foti, Caterina, Vena, Gino Antonio, and Marzano, Angelo Valerio

Subjects
BULLOUS pemphigoid, PSORIASIS, AUTOIMMUNE diseases, INFLAMMATION, SOFT tissue injuries
Abstract

The coexistence of psoriasis with autoimmune bullous diseases (AIBDs), particularly bullous pemphigoid (BP), has been documented in case reports and series, as well as in epidemiological studies. The onset of psoriasis precedes that of BP in the majority of cases. Patients with concomitant BP and psoriasis are generally younger at the onset of BP and present with fewer erosions and blisters as compared with patients suffering from isolated BP. Intriguingly, it has been speculated that some BP cases with comorbid psoriasis can actually correspond to anti-laminin gamma-1 pemphigoid, a rare form that was recently recognized as a distinct entity and which can mimic BP and/or other subepidermal AIBDs. The pathomechanisms underlying the BP–psoriasis association have not yet been identified, although several hypotheses have been proposed. The most credited among such hypotheses involves the so-called "epitope spreading" phenomenon, with tissue injury secondary to a primary inflammatory process (i.e., psoriasis) leading to the exposure of sequestered antigens evoking a secondary autoimmune disease (i.e., bullous pemphigoid). This narrative review aims to give a brief overview of the association between psoriasis and BP, examining epidemiological, clinical, and immunopathological features, the pathomechanisms underlying this association, the treatments for psoriasis incriminated as potential triggers of BP, and the therapeutic management of patients with psoriasis and BP. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

25. Reply to Scalone and Cortesi: “Cost-Utility Analysis of Biologic Therapies to Treat Chronic Plaque Psoriasis in Italy: The Importance of Using Updated and Adequate Social Tariffs to Calculate QALYs”

Author

Spandonaro, Federico, Ayala, Fabio, Berardesca, Enzo, Chimenti, Sergio, Girolomoni, Giampiero, Martini, Patrizia, Peserico, Andrea, Polistena, Barbara, Guerra, Antonio Puglisi, Vena, Gino Antonio, Altomare, Gianfranco, and Pinton, Piergiacomo Calzavara

Published
2015
Full Text
View/download PDF

42. Analysis of clinical factors as possible predictors of response to omalizumab and relapse after treatment discontinuation in chronic spontaneous urticaria.

Author

Foti, Caterina, Romita, Paolo, Ambrogio, Francesca, Fanelli, Margherita, Panebianco, Rosanna, Vena, Gino Antonio, Cassano, Nicoletta, Ragusa, Mariagrazia, Giuffrida, Roberta, Papaianni, Valeria, Borgia, Francesco, Cannavò, Serafinella Patrizia, and Guarneri, Fabrizio

Subjects
URTICARIA, TERMINATION of treatment, OMALIZUMAB, THYROID diseases, FACTOR analysis, MONOCLONAL antibodies, DISEASE relapse
Abstract

Omalizumab is a monoclonal anti‐IgE antibody which is effective in chronic spontaneous urticaria (CSU), although clinical response appears to be variable in the real‐life setting. The aim of this study was to evaluate whether the response of CSU to omalizumab and disease relapse are associated with individual and/or clinical characteristics of patients. We retrospectively evaluated the clinical records of 124 patients treated with omalizumab for moderate to severe CSU refractory to antihistamines. Disease activity was assessed using the urticaria activity score over the last 7 days (UAS7). After 24 weeks of treatment, 91% of patients showed complete remission (UAS7 = 0) or good control (UAS7 < 7) of CSU. Omalizumab was re‐administered in 45 patients because of recurrence of moderate to severe symptoms at week 8 after treatment discontinuation or later, and clinical results achieved with retreatment were similar to those observed in the first course. Among the parameters included in our analysis (age and sex of patients, documented history of atopy or autoimmune thyroid disease, CSU duration and baseline severity, concurrent angioedema, and association with chronic inducible urticaria), none was associated with response to omalizumab in our study population. Similarly, these parameters did not significantly differ between patients who experienced CSU relapse and those without relapse. Predictors of response to omalizumab treatment in CSU patients are still unclear, and further studies are needed to evaluate the presence of baseline factors that can influence treatment outcome. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

43. Multisystem Inflammatory Syndrome in Children Associated with COVID-19: A Review with an Emphasis on Mucocutaneous and Kawasaki Disease-Like Findings.

Author

Marzano, Angelo Valerio, Cassano, Nicoletta, Moltrasio, Chiara, Verdoni, Lucio, Genovese, Giovanni, and Vena, Gino Antonio

Subjects
MULTISYSTEM inflammatory syndrome in children, MULTISYSTEM inflammatory syndrome, TOXIC shock syndrome, COVID-19, MUCOCUTANEOUS lymph node syndrome
Abstract

Background: COronaVIrus Disease 2019 (COVID-19) affects children with less severe symptoms than adults. However, severe COVID-19 paediatric cases are increasingly reported, including patients with Kawasaki disease (KD) or a multisystem inflammatory syndrome (MIS-C) that can present with features resembling KD. Summary: MIS-C is an emerging severe paediatric syndrome associated with COVID-19 that can show overlapping features of KD, KD shock syndrome, and toxic shock syndrome. MIS-C might be an inflammatory disease distinct from KD resulting from an exaggerated immune response. A high prevalence of mucocutaneous manifestations – in addition to gastrointestinal and cardiovascular involvements – was found in MIS-C. The most frequent mucocutaneous findings were conjunctivitis and rash, often described as macular and/or papular or polymorphous. In this article, we present a brief overview of MIS-C with an emphasis on mucocutaneous findings and the relationship with KD. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

50. Psoriasis in pregnancy: challenges and solutions

Author

Vena, Gino Antonio, Cassano,Nicoletta, Bellia,Gilberto, and Colombo,Delia

Subjects
Targets and Therapy [Psoriasis]
Abstract

Gino Antonio Vena,1 Nicoletta Cassano,1 Gilberto Bellia,2 Delia Colombo,2 1Dermatology and Venereology Private Practice, Bari and Barletta, 2Novartis Farma SpA, Origgio, Varese, Italy Abstract: The available information about the effects of pregnancy on psoriasis and those of psoriasis on pregnancy is almost limited, despite the high frequency of the disease in the general population, as well as in women in reproductive years. Considering the existing evidence, pregnancy does not tend to have a negative influence on psoriasis, as in most women who experience a change in the severity and course of their psoriasis during pregnancy, the change is more likely to be reported as an improvement. This assumption can be applied more convincingly to plaque-type psoriasis, while an exception may be represented by generalized pustular psoriasis, which has been somehow linked to impetigo herpetiformis. Conflicting findings emerged from the few available studies that explored the effect of psoriasis on pregnancy outcomes. Recent studies found an association between moderate-to-severe psoriasis and some pregnancy complications, including pregnancy-induced hypertensive diseases, and have emphasized a trend toward a newborn with low birth weight in patients with psoriasis, especially in those suffering from severe forms. The safety profile during pregnancy is not completely known for many drugs used to treat psoriasis. Moisturizers and low- to moderate-potency topical steroids or ultraviolet B phototherapy represent the first-line therapy for pregnant patients. Many dermatologists may, however, recommend discontinuing all drugs during pregnancy, in consideration of medico-legal issues, and also taking into account that common forms of psoriasis do not compromise the maternal and fetal health. Anyway, for those women whose psoriasis improves during pregnancy, the interruption of any therapy for psoriasis can be a reasonable strategy. The objective of this paper was to review the most relevant literature data on psoriasis in pregnancy, trying to give concurrently practical information about clinical and prognostic aspects, as well as counseling and management. Keywords: psoriasis, pregnancy, treatment, management, outcome, topical/systemic drugs, phototherapy

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results